Literature DB >> 10574910

Novel human N-acetyltransferase 2 alleles that differ in mechanism for slow acetylator phenotype.

M A Leff1, A J Fretland, M A Doll, D W Hein.   

Abstract

Three novel human NAT2 alleles (NAT2*5D, NAT2*6D, and NAT2*14G) were identified and characterized in a yeast expression system. The common rapid (NAT2*4) and slow (NAT2*5B) acetylator human NAT2 alleles were also characterized for comparison. The novel recombinant NAT2 allozymes catalyzed both N- and O-acetyltransferase activities at levels comparable with NAT2 5B and significantly below NAT2 4, suggesting that they confer slow acetylation phenotype. In order to investigate the molecular mechanism of slow acetylation in the novel NAT2 alleles, we assessed mRNA and protein expression levels and protein stability. No differences were observed in NAT2 mRNA expression among the novel alleles, NAT2*4 and NAT2*5B. However NAT2 5B and NAT2 5D, but not NAT2 6D and NAT2 14G protein expression were significantly lower than NAT2 4. In contrast, NAT2 6D was slightly (3.4-fold) and NAT2 14G was substantially (29-fold) less stable than NAT2 4. These results suggest that the 341T --> C (Ile(114) --> Thr) common to the NAT2*5 cluster is sufficient for reduction in NAT2 protein expression, but that mechanisms for slow acetylator phenotype differ for NAT2 alleles that do not contain 341T --> C, such as the NAT2*6 and NAT2*14 clusters. Different mechanisms for slow acetylator phenotype in humans are consistent with multiple slow acetylator phenotypes.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10574910     DOI: 10.1074/jbc.274.49.34519

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  23 in total

1.  Genetic and small molecule inhibition of arylamine N-acetyltransferase 1 reduces anchorage-independent growth in human breast cancer cell line MDA-MB-231.

Authors:  Marcus W Stepp; Mark A Doll; Samantha M Carlisle; J Christopher States; David W Hein
Journal:  Mol Carcinog       Date:  2018-02-03       Impact factor: 4.784

2.  Effect of efavirenz-based antiretroviral therapy and high-dose rifampicin on the pharmacokinetics of isoniazid and acetyl-isoniazid.

Authors:  Maxwell T Chirehwa; Helen McIlleron; Lubbe Wiesner; Dissou Affolabi; Oumou Bah-Sow; Corinne Merle; Paolo Denti
Journal:  J Antimicrob Chemother       Date:  2019-01-01       Impact factor: 5.790

3.  Codominant expression of N-acetylation and O-acetylation activities catalyzed by N-acetyltransferase 2 in human hepatocytes.

Authors:  Mark A Doll; Yu Zang; Timothy Moeller; David W Hein
Journal:  J Pharmacol Exp Ther       Date:  2010-04-29       Impact factor: 4.030

4.  Variation in N-acetyltransferase 2 (NAT2), smoking and risk of prostate cancer in the Slovak population.

Authors:  Marta Vilčková; Jana Jurečeková; Dušan Dobrota; Viera Habalová; Lucia Klimčáková; Iveta Waczulíková; Peter Slezák; Ján Kliment; Monika Kmeťová Sivoňová
Journal:  Med Oncol       Date:  2014-05-11       Impact factor: 3.064

5.  Association of NAT2 genetic polymorphism with the efficacy of Neurotropin® for the enhancement of aggrecan gene expression in nucleus pulposus cells: a pilot study.

Authors:  Tomoko Nakai; Daisuke Sakai; Yoshihiko Nakamura; Natsumi Horikita; Erika Matsushita; Mitsuru Naiki; Masahiko Watanabe
Journal:  BMC Med Genomics       Date:  2021-03-11       Impact factor: 3.063

6.  Role of the N-acetylation polymorphism in solithromycin metabolism.

Authors:  David W Hein; Mark A Doll
Journal:  Pharmacogenomics       Date:  2017-04-24       Impact factor: 2.533

Review 7.  Pharmacogenetics in inflammatory bowel disease.

Authors:  Marie Pierik; Paul Rutgeerts; Robert Vlietinck; Severine Vermeire
Journal:  World J Gastroenterol       Date:  2006-06-21       Impact factor: 5.742

8.  Crohn's disease in Japanese is associated with a SNP-haplotype of N-acetyltransferase 2 gene.

Authors:  Haruhisa Machida; Kazuhiro Tsukamoto; Chun-Yang Wen; Saburou Shikuwa; Hajime Isomoto; Yohei Mizuta; Fuminao Takeshima; Kunihiko Murase; Naomichi Matsumoto; Ikuo Murata; Shigeru Kohno; Chen-Yang Wen
Journal:  World J Gastroenterol       Date:  2005-08-21       Impact factor: 5.742

9.  Arylamine N-acetyltransferase 2 slow acetylator polymorphisms in unrelated Iranian individuals.

Authors:  Valery V Bakayev; Forozan Mohammadi; Moslem Bahadori; Mariam Sheikholslami; Arash Javeri; Mohammad R Masjedi; Ali A Velayati
Journal:  Eur J Clin Pharmacol       Date:  2004-09       Impact factor: 2.953

10.  Polymorphisms of promoter and coding regions of the arylamine N-acetyltransferase 2 (NAT2) gene in the Indonesian population: proposal for a new nomenclature.

Authors:  Rika Yuliwulandari; Qomariyah Sachrowardi; Nao Nishida; Miwa Takasu; Lilian Batubara; Tri Panjiasih Susmiarsih; Jecti Teguh Rochani; Riyani Wikaningrum; Risa Miyashita; Taku Miyagawa; Abdul Salam Mudzakir Sofro; Katsushi Tokunaga
Journal:  J Hum Genet       Date:  2007-12-27       Impact factor: 3.172

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.